Evidence map›Paper›PMID 41480176›Full record

ReviewWorld journal of clinical oncology2025

Immune therapy-related hyperprogressive disease: Molecular mechanisms, biomarkers, and clinical strategies.

Xiao-Ming Zhang, Fei-Yu Zhao, Lin-Feng Gao, Tao Xu, Fan Yang, Nian-Song Qian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiao-Ming ZhangDepartment of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China.
Fei-Yu ZhaoDepartment of Radiation Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
Lin-Feng GaoDepartment of Oncology, The 93263 Unit of The Chinese PLA, Jinzhou 100039, Liaoning Province, China.
Tao XuDepartment of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China.
Fan YangDepartment of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China.
Nian-Song QianDepartment of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100091, China. qianniansong1@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed death receptor-1 inhibitors have significantly improved the prognosis of various malignancies. Nevertheless, hyperprogressive disease (HPD), recognized as a severe adverse reaction to immunotherapy, causes a substantial surge in tumor burden and notably shortens the survival of 4%-29% of patients. This article comprehensively reviews the controversies regarding the clinical definition of HPD, its cross-cancer epidemiological features (encompassing gastric cancer, non-small cell lung cancer, head and neck squamous cell carcinoma,

Indexed as

Combination therapyHyperprogressive diseaseImmune checkpoint inhibitorsPredictive biomarkersRegulatory T cellsTumor microenvironment

Identifiers

PMID41480176
PMCPMC12754105

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.